CLDX vs NEOG
Celldex Therapeutics, Inc. and Neogen Corp., side by side — 10 fiscal years reported in USD, drawn from SEC filings.
Most recent reported year
| Metric | CLDX | NEOG |
|---|---|---|
| Revenue | $1.5M | $870.4M |
| Net income | $-258.8M | $-7.9M |
| Gross margin | 87.1% | 46.9% |
| Net margin | · | −0.9% |
| Return on equity | −40.6% | −0.4% |
| Diluted EPS | −$3.90 | −$0.04 |
| Dividend / share | · | · |
| Payout ratio | · | · |
| Free cash flow | $-213.7M | $31.9M |
| Equity | $527.2M | $2.1B |
| Net debt / equity | · | 0.29× |
| Current ratio | 10.49× | 3.82× |
| Revenue CAGR 5y | −26.9% | 13.2% |
| Profit CAGR 5y | · | · |
NEOG bills 563.4× the revenue of CLDX, and both closed the last reported year at a loss.
The stronger figure of the pair is set in bold. That is arithmetic, not a recommendation — this page does not pick a winner. "·" marks a figure not available in our data.
10 years side by side
| Fiscal year | CLDX | NEOG |
|---|---|---|
| FY2025 | $1.5M | $870.4M |
| FY2024 | $7.0M | $894.7M |
| FY2023 | $6.9M | $924.2M |
| FY2022 | $2.4M | $822.4M |
| FY2021 | $4.7M | $527.2M |
| FY2020 | $7.4M | $468.5M |
| FY2019 | $3.6M | $418.2M |
| FY2018 | $9.5M | $414.2M |
| FY2017 | $12.7M | $397.9M |
| FY2016 | $6.8M | $358.3M |
Bottom line
| Fiscal year | CLDX | NEOG |
|---|---|---|
| FY2025 | $-258.8M | $-7.9M |
| FY2024 | $-157.9M | $-1.1B |
| FY2023 | $-141.4M | $-9.4M |
| FY2022 | $-112.3M | $-22.9M |
| FY2021 | $-70.5M | $48.3M |
| FY2020 | $-59.8M | $60.9M |
| FY2019 | $-50.9M | $59.5M |
| FY2018 | $-151.2M | $60.2M |
| FY2017 | $-93.0M | $63.1M |
| FY2016 | $-128.5M | $43.8M |
17 fiscal years
| Fiscal year | Difference | Ahead |
|---|---|---|
| FY2025 | −$868,855,000 | NEOG |
| FY2024 | −$887,680,000 | NEOG |
| FY2023 | −$917,317,000 | NEOG |
| FY2022 | −$820,090,000 | NEOG |
| FY2021 | −$522,508,000 | NEOG |
| FY2020 | −$461,041,000 | NEOG |
| FY2019 | −$414,597,000 | NEOG |
| FY2018 | −$404,648,000 | NEOG |
| FY2017 | −$385,187,000 | NEOG |
| FY2016 | −$351,491,000 | NEOG |
| FY2015 | −$315,795,000 | NEOG |
| FY2014 | −$279,488,000 | NEOG |
| FY2013 | −$243,294,000 | NEOG |
| FY2012 | −$196,326,000 | NEOG |
| FY2011 | −$174,781,000 | NEOG |
| FY2010 | −$125,890,000 | NEOG |
| FY2009 | −$125,329,000 | NEOG |
NEOG has reported the higher revenue in every one of these 17 fiscal years. The gap has widened since the earliest year compared.
17 of 17 comparable fiscal years — a year missing data on either side is not counted.
Standard deviation, each side
CLDX's return on equity has been more volatile than NEOG's over the 17 comparable fiscal years — 18.0 percentage points of standard deviation against 12.6.
17 of 17 comparable fiscal years — a year missing data on either side is not counted.
Year by year
The lead in return on equity changed hands between CLDX and NEOG over these 17 fiscal years — CLDX led in 1 and NEOG in 16.
17 of 17 comparable fiscal years — a year missing data on either side is not counted.